KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Non-Current Liabilities (2019 - 2025)

Esperion Therapeutics' Total Non-Current Liabilities history spans 7 years, with the latest figure at $759.1 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 3.63% year-over-year to $759.1 million; the TTM value through Dec 2025 reached $759.1 million, up 3.63%, while the annual FY2025 figure was $759.1 million, 3.63% up from the prior year.
  • Total Non-Current Liabilities reached $759.1 million in Q4 2025 per ESPR's latest filing, down from $807.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $807.9 million in Q3 2025 to a low of $332.8 million in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $497.9 million, with a median of $400.9 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 617.54% in 2021, then plummeted 41.73% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $332.8 million in 2021, then grew by 6.03% to $352.9 million in 2022, then rose by 19.26% to $420.8 million in 2023, then surged by 74.07% to $732.5 million in 2024, then increased by 3.63% to $759.1 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Total Non-Current Liabilities are $759.1 million (Q4 2025), $807.9 million (Q3 2025), and $773.2 million (Q2 2025).